Can-Fite details 28-month Namodenoson cirrhosis case
Rhea-AI Filing Summary
Can-Fite BioPharma Ltd. (CANF) reports a peer-reviewed case describing a patient with advanced decompensated liver cirrhosis treated with its drug candidate Namodenoson, who showed resolution of ascites, regression of esophageal varices, and remained clinically stable for approximately 28 months before a successful liver transplant in January 2026. The treating physician noted that improvements in portal-hypertension complications occurred despite continued deterioration in hepatic synthetic function and viewed the case as supporting further evaluation of Namodenoson in advanced liver disease. Namodenoson, an A3 adenosine receptor agonist, is already in a pivotal Phase 3 trial for hepatocellular carcinoma and a Phase 2b trial for MASH, and has Orphan Drug Designation in the U.S. and Europe and Fast Track status from the FDA for second-line HCC.
Positive
- None.
Negative
- None.
Filing Explained
This Form 6-K furnishes the September 9 press release as interim information and incorporates its first paragraph by reference into specified Form S-8 and Form F-3 registration statements, adding that disclosure to those filings without changing the completed clinical case described.
Key Figures
Duration of clinical stability on Namodenoson: Approximately 28 months
Liver transplant timing: January 2026
Patients exposed to Can-Fite drug candidates: More than 1,700 patients
+2 more
5 metrics
Duration of clinical stability on Namodenoson
Approximately 28 months
Patient with advanced decompensated cirrhosis remained clinically stable before liver transplant
Liver transplant timing
January 2026
Date of successful orthotopic liver transplantation after Namodenoson treatment
Patients exposed to Can-Fite drug candidates
More than 1,700 patients
Clinical studies of Can-Fite’s drug candidates to date
Orphan Drug Designation regions
United States and Europe
Regulatory designations granted to Namodenoson for hepatocellular carcinoma
Fast Track Designation
Second-line HCC treatment
FDA Fast Track indication for Namodenoson
Key Terms
decompensated cirrhosis, orthotopic liver transplantation, Metabolic Dysfunction-associated Steatohepatitis (MASH), Orphan Drug Designation, +2 more
6 terms
decompensated cirrhosis medical
"a patient with advanced decompensated liver cirrhosis treated with Namodenoson"
An advanced stage of chronic liver disease in which the liver can no longer carry out key tasks, causing serious complications such as fluid buildup in the abdomen, bleeding from damaged blood vessels, and mental confusion. Think of the liver as a factory breaking down and creating system-wide backups; patients with decompensated cirrhosis often need urgent medical care or long-term treatments, which matters to investors because it drives demand for therapies, influences clinical trial design, and affects healthcare costs and regulatory risks.
orthotopic liver transplantation medical
"the patient underwent successful orthotopic liver transplantation from a deceased donor"
Surgical replacement of a failing or diseased liver with a healthy liver or liver segment placed into the same anatomical position in the recipient, using an organ from a deceased or living donor. It matters to investors because the procedure drives revenue and costs for hospitals, transplant centers, device makers, drug companies (immunosuppressants), and insurers, and changes in surgical volume, regulation, reimbursement, or outcomes can affect the financial performance of those businesses — like swapping a car’s engine and paying for the parts, labor, and ongoing maintenance.
Metabolic Dysfunction-associated Steatohepatitis (MASH) medical
"a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)"
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition characterized by inflammation and fat buildup caused by metabolic issues like obesity and insulin resistance. It can lead to liver damage over time, similar to rust gradually weakening metal. Because it is linked to widespread health problems such as diabetes and heart disease, MASH is becoming an important factor in overall health risks and healthcare costs, which can impact economic and investment considerations.
Orphan Drug Designation regulatory
"Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"Fast Track Designation by the U.S. Food and Drug Administration as a second-line treatment"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
A3 adenosine receptor (A3AR) medical
"Namodenoson is a highly selective agonist of the A3 adenosine receptor (A3AR)"
A3 adenosine receptor (A3AR) is a specific protein on the surface of cells that acts like a lock for the natural molecule adenosine, triggering signals that can reduce inflammation, control cell growth, or affect pain perception. It matters to investors because medicines that activate or block this receptor are drug development targets; success or failure in clinical trials, regulatory review, or partnerships around A3AR-targeting therapies can significantly change a biotech company’s value, much like a key unlocking commercial potential.
FAQ
What clinical finding did CANF report in this 6-K regarding Namodenoson?
The company reported a peer-reviewed case of a patient with advanced decompensated cirrhosis treated with Namodenoson who experienced resolution of ascites, regression of esophageal varices, and remained clinically stable for about 28 months before undergoing successful liver transplantation in January 2026.
How long was the CANF Namodenoson-treated cirrhosis patient stable before transplant?
The patient remained clinically stable for approximately 28 months while on Namodenoson treatment and then underwent a successful orthotopic liver transplantation from a deceased donor in January 2026, with a favorable post-transplant recovery reported.
What stage of development is Namodenoson in according to CANF’s 6-K?
Namodenoson is being evaluated in a pivotal Phase 3 trial for advanced hepatocellular carcinoma, has completed a Phase 2a study in pancreatic cancer, and is currently enrolling a Phase 2b trial for Metabolic Dysfunction-associated Steatohepatitis (MASH).
What regulatory designations has Namodenoson received, as disclosed by CANF?
Namodenoson has Orphan Drug Designation in both the U.S. and Europe and Fast Track Designation from the U.S. Food and Drug Administration as a second-line treatment for hepatocellular carcinoma (HCC).
What is the mechanism of action of Namodenoson mentioned in the CANF filing?
Namodenoson is described as a highly selective agonist of the A3 adenosine receptor (A3AR), which is highly expressed in inflammatory and pathological cells and has been reported to exert anti-inflammatory and anti-fibrotic effects through pathways including NF-κB and Wnt/β-catenin.
What broader clinical safety experience with CANF’s drugs is noted in the 6-K?
Can-Fite states that its drug candidates, including Piclidenoson and Namodenoson, have shown a favorable safety profile in clinical studies involving more than 1,700 patients to date across various indications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
